Orasis Pharmaceuticals Overview
Orasis is an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, for presbyopia as an alternative to reading glasses. Presbyopia is the gradual loss of your eye’s ability to focus on near objects, which begins to affect most people sometime after the age of 40 and affects more than 1.8 billion people worldwide. Orasis is led by a collaborative team of industry executives, Optometrists and Ophthalmologists with a diverse set of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Orasis Announces Licensing Agreement With Optus Pharmaceuticals for Commercialization of Qlosi Eye Drops in Korea
Orasis Pharmaceuticals has entered into an exclusive licensing agreement with Optus Pharmaceuticals, allowing the latter to commercialize, import, and sell Orasiss novel eye drop, Qlosi, in Korea. This agreement is part of Orasiss strategy to expand its global reach and follows its recent Series D financing. The deal includes an upfront payment and milestone payments totaling $18 million, along with double-digit royalties on sales. Optus plans to launch Qlosi in Korea by 2026, pending regulatory approvals. This partnership is a significant step for Orasis in offering innovative solutions for presbyopia treatment worldwide.
Partners
growth-positive
Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%
Orasis Pharmaceuticals announced the completion of a $78 million financing round to support the commercial launch of Qlosi, a corrective eye drop for presbyopia treatment. The Series D financing included a $68 million equity component co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc., with participation from several other investors. Additionally, Orasis secured $15 million in structured capital from Catalio Capital Management, with $10 million drawn at closing. This funding will enable Orasis to launch Qlosi, providing a novel solution for presbyopia patients. The investment reflects confidence in Orasiss potential to impact the eye care market positively.
Investment
growth-positive
Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia
Orasis Pharmaceuticals has received FDA approval for QLOSI, a preservative-free, low-dose eye drop designed to treat presbyopia in adults. This approval is a significant milestone for the company, as QLOSI demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials. The eye drop is expected to be commercially available in the U.S. in the first half of 2024. Orasis is backed by several investors, including Visionary Ventures and Sequoia Capital. The approval is based on trials involving over 600 patients, showing significant improvement in near visual acuity. The company aims to provide a flexible treatment option for the millions affected by presbyopia.
Customers
growth-positive
FDA Accepts Orasis Pharmaceuticals' New Drug Application for CSF-1 for the Treatment of Presbyopia
Orasis Pharmaceuticals announced that the FDA has accepted its New Drug Application for CSF-1, an investigational eye drop for treating presbyopia, with a PDUFA goal date set for October 22, 2023. The NDA is supported by Phase 3 clinical trials involving over 600 patients, which demonstrated significant improvements in near visual acuity. The acceptance of the NDA is a positive step towards the potential approval and commercial launch of CSF-1, addressing a significant unmet need for presbyopia treatment. Orasis is backed by several investors, including Visionary Ventures and Sequoia Capital.
growth-positive
Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia
Orasis Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational CSF-1, a unique eye drop to improve near vision for people with presbyopia. The NDA is based on positive data from Phase 3 NEAR-1 and NEAR-2 clinical trials, which met primary and key secondary endpoints. The trials demonstrated statistically significant improvement in near visual acuity and minimal adverse events. With over 120 million people affected by presbyopia in the U.S., Orasis aims to provide an alternative treatment option. The company is funded by a diverse group of investors including Visionary Ventures, Sequoia Capital, and SBI (Japan) Innovation Fund.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $121M |
| Last funding | $78M |
| Stage | D |
| Rounds | 5 |
| Investors | 12 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | www.orasis-pharma.com/ |
Locations
Maskit St 6, Herzliya, Israel
101 Marketside Avenue, Ponte Vedra Beach, FL 32081, USA
Photos & Videos
1 item(s)
